Navigation Links
InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights
Date:2/26/2009

BRISBANE, Calif., Feb. 26 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced results from operations for the fourth quarter and 12 months ended December 31, 2008. InterMune reported a net loss for the fourth quarter of 2008 of $32.3 million, or $0.83 per share, compared with a net loss of $25.9 million, or $0.67 per share, in the fourth quarter of 2007.

Dan Welch, Chairman, Chief Executive Officer and President of InterMune said, "Fourth quarter and recent events have highlighted our very significant progress on pirfenidone and ITMN-191 (R7227). We recently reported results of our Phase 3 CAPACITY program for pirfenidone in idiopathic pulmonary fibrosis (IPF) and are now preparing the New Drug Application (NDA) and Marketing Authorization Application (MAA) for the United States and European Union, respectively. We also reported very positive top-line results of our triple combination study of ITMN-191 with Pegasys(R) (pegylated interferon alfa-2a) and Copegus(R) (ribavirin) and launched the innovative all-oral treatment study, INFORM-1, in patients chronically infected with the hepatitis C virus (HCV)."

Results for Fourth Quarter 2008

InterMune reported total revenue in the fourth quarter of 2008 of $7.4 million, compared with total revenue of $9.6 million in the fourth quarter of 2007. Total revenue in the fourth quarter of 2008 primarily consisted of Actimmune(R) (interferon gamma-1b) revenue of $6.6 million, compared with $8.8 million in the fourth quarter of 2007, a decrease of 25%, reflecting lower off-label physician prescriptions of Actimmune for the treatment of IPF, which InterMune does not promote. Fourth quarter total revenue also included revenue from the collaboration with Roche for the development of protease inhibitors, including ITMN-191, which totaled
'/>"/>

SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 26
2. InterMune Announces Issuance of U.S. Patent for ITMN-191
3. InterMune Announces Pricing of Public Offering of 3,500,000 Shares of Common Stock
4. InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
5. InterMune to Present at J.P. Morgan Healthcare Conference
6. InterMune to Present at Deutsche Bank Biotech Boston Confab
7. InterMune Reports Third Quarter 2008 Financial Results and Business Highlights
8. InterMune to Release Third Quarter 2008 Financial Results on November 6
9. InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF
10. InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting
11. InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... , Nov. 25, 2014  Roka Bioscience, Inc. (NASDAQ: ... providing advanced testing solutions for the detection of foodborne pathogens, ... at the Piper Jaffray  26 th Annual Healthcare Conference ... be held at The New York Palace in ... presentation, material information concerning the Company, its operations, strategies and ...
(Date:11/24/2014)... , UAE, November 24, 2014 ... Hamdan Bin Rashid Al Maktoum Awards for Medical Sciences", ... Dubai, United Arab Emirates , on 15 ... ) , The Carter Center which won ... is actively involved in numerous programs that aim to ...
(Date:11/24/2014)... Nov. 24, 2014 VolitionRx Limited (OTCQB: ... for cancer and other conditions, today announced that data from ... Science for Business BioWin Day 2014, being held November 26, ... come from VolitionRx,s lung cancer pilot study, the samples for ... Hospitalier Universitaire (CHU) de Liege in Belgium ...
(Date:11/24/2014)... 24, 2014   Veracyte, Inc. (Nasdaq: ... president and chief executive officer, will present in a fireside ... Healthcare Conference on Tuesday, December 2, 2014 at 12:30 p.m. ... The live audio webcast and subsequent replay may be accessed ... to the website at least 15 minutes prior to the ...
Breaking Biology Technology:Roka Bioscience to Present at the Piper Jaffray Healthcare Conference 2Five US Winners Among Recipients of Hamdan Medical Awards 2VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 2VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 3VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 4VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 5VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 6Veracyte to Present at the Piper Jaffray 26th Annual Healthcare Conference 2
... management services for biopharmaceutical and medical device clinical trials, announced today ... how state-of-the-art image management can enhance DXA (Dual Energy X-Ray Absorptiometry) ... consider in trials using body composition measurements with DXA. , ... ...
... Value of Pharmaceuticals in a New U.S. Political ... the start of the first annual conference on ... Industry at the Loews Philadelphia Hotel. The ... insights needed to prepare for future changes in ...
... 9 Sagent Pharmaceuticals, Inc., a,privately-held specialty pharmaceutical ... injection, USP, an essential antibiotic used to treat,serious ... The 500mg single-dose vial expands ... single-dose vials and 10g pharmacy bulk package vials,launched ...
Cached Biology Technology:Free DXA Bone Mineral Density and Body Composition in Clinical Trials Webinars to be Held by M2S DXA Division Expert 2ExL Pharma Presents The Pharmaceutical Managed Markets Insight & Marketing for the Pharmaceutical Industry Conference 2ExL Pharma Presents The Pharmaceutical Managed Markets Insight & Marketing for the Pharmaceutical Industry Conference 3Sagent Pharmaceuticals Announces Expansion of Cefazolin Product Line to Include Cefazolin for Injection, USP in 500mg Single-Dose Vial 2
(Date:11/6/2014)... is an asset for a predator. Except when that predator ... tiger beetle, relative to its size, is the fastest creature ... body lengths per second (at about five miles per hour). ... take the sprinting gold from the tiger beetle, a person ... The tiger beetle has a problem. At peak speeds, everything ...
(Date:11/5/2014)... his career to understanding the Earth,s climate and ... As deputy director and regional climatologist for the ... Institute, Redmond has more than three decades of ... climate data to the general public. , At ... on December 15-19, 2014 the American Geophysical Union ...
(Date:11/4/2014)... amount of death at the right time might actually ... research that could help in understanding animal populations, pest ... a paper in the journal Trends in Ecology ... colleagues conclude that the kind of positive population effect ... or mortality, depends on the size and developmental stage ...
Breaking Biology News(10 mins):The tiger beetle: Too fast to see 2Nevada climatologist to be honored at AGU Fall Meeting for lifetime of public outreach 2When less is more: Death in moderation boosts population density in nature 2
... LAWRENCE, KAN. A new candidate gene for Specific ... directed by Mabel Rice at the University of Kansas, ... Center, and Javier Gayn of Neocodex, Seville, Spain. The ... Journal of Neurodevelopmental Disorders , was discovered by examining ...
... temperatures soar, scientists have been collecting data amid the ... These data, combined with measurements from aircraft and satellites, ... life in modern-day Athens easier during heat waves. ... months across southern Europe but the Greek capital of ...
... means Kansas State University ecologists will get more help ... opportunities for eight to 10 undergraduate students each summer ... Jumpponen, associate professors of biology, and Bruce Snyder, instructor ... National Science Foundation to help K-State continue to be ...
Cached Biology News:Researchers report gene associated with language, speech and reading disorders 2ESA helps make summer in the city more bearable 2ESA helps make summer in the city more bearable 3ESA helps make summer in the city more bearable 4
... Drosophila S2 cells are used for heterologous ... System (DES). The S2 cell line was ... (20-24 hours old) Drosophila melanogaster embryos ... at room temperature without CO2 and is easily ...
... syringe pump series combines Harvard Apparatuss best pump ... a wide range of configuration options. A lookup ... of syringes from all the major manufacturers. A ... the pertinent information from across the lab. All ...
... novel expression vectors, we in-troduced a new concept, ... at tran-scriptional level at the T7 phage promoter, ... amplifying the plasmid copy number, The main advantage ... retains practically all of the outstanding features of ...
... This CLS number is a new product ... number. If showing no availability yet, please ... or contact customer service for assistance. ... Comp Dim: surface area 21 cm 2 ...
Biology Products: